Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome

Abstract

The dermatological manifestations of antiphospholipid syndrome (APS) may be the presenting features of APS syndrome. They are extremely diverse and heterogeneous, ranging from minor signs to life-threatening conditions such as widespread cutaneous necrosis. Their clinical significance is highly variable. Livedo reticularis is strongly associated with the arterial and microangiopathic subtypes of APS. Scientific data are required to determine the optimum management of these patients, who might benefit from recently developed antithrombotic agents. Lupus (2010) 19, 1071—1077.

Keywords

anetoderma antiphospholipid syndrome livedo reticularis lupus anticoagulant necrosis thrombosis

Get full access to this article

View all access options for this article.

References

Hughes GRV. Connective tissue disease and the skin. The Prosser-White Oration 1983. Clin Exp Dermatol 1984; 9: 535-544.

Frances C. , Niang S. , Laffitte E. , Pelletier FL , Costedoat N. , Piette JC Dermatologic manifestations of the antiphospholipid syndrome: Two hundred consecutive cases. Arthritis Rheum 2005; 52: 1785-1793.

Toubi E. , Krause I. , Fraser A. , et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23: 499-504.

Cervera R. , Piette JC , Font J. , et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.

Uthman IW , Khamashta MA Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome . J Rheumatol 2006; 33: 2379-2382.

García-Carrasco M. , Galarza C. , Gómez-Ponce M. , et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus 2007; 16: 366-373.

Avcin T. , Cimaz R. , Silverman ED , et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008; 122: 1100-1107.

Francès C. , Papo T. , Wechsler B. , Laporte JL , Biousse V. , Piette JC Sneddon syndrome with or without antiphospholipid antibodies: a comparative study in 46 patients . Medicine 1999; 78: 209-219.

Weinstein S. , Piette W. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am 2008; 22: 67-77.

10.

Miyakis S. , Lockshin MD , Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.

11.

Bowie EJ , Thompson JH , Pascuzzi CA , Owen CA Thrombosis in systemic lupus erythematosus despite circulating anticoagulants . J Lab Clin Med 62: 416-430.

12.

Alarcón-Segovia D. , Delezé M. , Oria CV , et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus . A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353-365.

13.

Acland KM , Darvay A. , Wakelin SH , Russell-Jones R.

Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?

Br J Dermatol 1999; 140: 131-135.

14.

Tran MD , Bécherel PA , Cordel N. , Piette JC , Francès C. Atrophie blanche ‘idiopathique’. Ann Dermatol Venereol 2001; 128: 1003-1007.

15.

Chacek S. , MacGregor-Gooch J. , Halabe-Cherem J. , Nellen-Hummel H. , Quinones-Galvan A. Pyoderma gangrenosum and extensive caval thrombosis associated with antiphospholipid syndrome - a case report. Angiology 1998; 49: 157-160.

16.

Schmid MH , Hary C. , Marstaller B. , Konz B. , Wendtner CM Pyoderma gangrenosum associated with the secondary antiphospholipid syndrome . Eur J Dermatol 1998; 8: 45-47.

17.

Bessis D. , Sotto A. , Viard JP , Bérard M. , Ciurana AJ , Boffa MC Trousseau’s syndrome with nonbacterial thrombotic endocarditis: pathogenic role of antiphospholipid syndrome. Am J Med 1995; 98: 511-513.

18.

Creamer D. , Black MM , Calonje E. Reactive angioendotheliomatosis in association with the antiphospholipid syndrome . J Am Acad Dermatol 2000; 42: 903-906.

19.

Hodak E. , David M. Primary anetoderma and antiphospholipid antibodies-review of the literature . Clin Rev Allergy Immunol 2007; 32: 162-166.

20.

Romani J. , Perez F. , Llobet, M. , Planaguma M. , Pujol RM Anetoderma associated with antiphospholipid antibodies. Case report and review of the literature. J Eur Acad Dermatol Venereol 2000; 15: 175-178.

21.

Sparsa A. , Piette JC , Wechsler B. , Amoura Z. , Francès C. Anetoderma and its prothrombotic abnormalities. J Am Acad Dermatol 2003; 49: 1008-1012.

22.

Stephansson EA , Niemi KM

Antiphospholipid antibodies and anetoderma; are they associated?

Dermatology 1995; 191: 204-209.

23.

Weinstein C. , Miller MH , Axtens R. , Buchanan R. , Littlejohn GO Livedo reticularis associated with increased titres of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol 1987; 123: 596-600.

24.

Nochy D. , Daugas E. , Huong DL , Piette JC , Hill G. Kidney involvement in the antiphospholipid syndrome. J Autoimmun 2000; 15: 127-132.

25.

Krause I. , Leibovici L. , Blank M. , Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 2007 ; 16: 176-180.

26.

Francès C. , Piette JC , Saada V. , et al. Multiple subungual splinter hemorrhages in the antiphospholipid syndrome. A report of five cases and review of the literature. Lupus 1994; 3: 123-128.

27.

Asherson RA The catastrophic antiphospholipid antibody syndrome . J Rheumatol 1992; 19: 508-512.

28.

Asherson RA , Cervera R. , Piette JC , et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients . Medicine 1998; 77: 195-207.

29.

Stojanovich L. , Marisavljevic D. , Rovensky J. , Djokovich A. , Kozáková D. , Milinic N. Clinical and laboratory features of the catastrophic antiphospholipid syndrome . Clin Rev Allergy Immunol 2009; 26: 7479.

30.

Toubi E. , Shoenfeld Y. Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allergy Immunol 2007; 32: 138-144.

31.

Rossini J. , Roverano S. , Graf C. , Paira S. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. J Clin Rheumatol 2002 ; 8: 326-331.

32.

Srinivasan SK , Pittelkow MR , Cooper Jr LT Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: a case report. Angiology 2001; 52: 635-639.

33.

Zahavi J. , Charach G. , Schafer R. , Toeg A. , Zahavi M. Ischemic necrotic toes associated with antiphospholipid syndrome and treated with iloprost. Lancet 1993; 342: 862.

34.

Francès C. , Tribout B. , Boisnic S. , et al. Cutaneous necrosis associated with the lupus anticoagulant. Dermatologica 1989 ; 178: 194-201.

35.

Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 2006; 6: 98-103.

36.

Cervera R. , Khamashta MA , Shoenfeld Y. , et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicenter prospective study of 1,000 patients. Ann Rheum Dis 2008; doi 10.1136/ard.2008.093179)

37.

Frances C. , Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol 2004; 140: 1011.

38.

Gertner E. Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. Lupus 2003 ; 12: 133-135.

39.

Del Castillo LF , Soria C. , Schoendorff C. , et al. Widespread cutaneous necrosis and antiphospholipid antibodies: two episodes related to surgical manipulation and urinary tract infection. J Am Acad Dermatol 1997; 36: 872-875.

40.

Rand JH , Wu XX , Quinn AS , Chen PP , Hathcock JJ , Taatjes DJ Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687-1695.